Role of endogenous vascular endothelial growth factor in endothelium-dependent vasodilation in humans

Hypertension

Volumn 61, Issue 5, 2013, Pages 1060-1065

  Thijs, Anna M J ^a   Van Herpen, Carla M L ^a   Sweep, Fred C G J ^a   Geurts Moespot, Anneke ^a   Smits, Paul ^a   Van Der Graaf, Winette T A ^a   Rongen, Gerard A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

angiogenesis inhibitors; endothelial function; human; vascular biology; VEGF

Indexed keywords

ACETYLCHOLINE; BEVACIZUMAB; NITROPRUSSIDE SODIUM; VASCULOTROPIN;

ADULT; ARTICLE; BLOOD VESSEL TONE; BRACHIAL ARTERY; CLINICAL TRIAL; ENDOTHELIUM; HUMAN; HUMAN EXPERIMENT; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PERIPHERAL CIRCULATION; PLETHYSMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; VASODILATATION; VEIN OCCLUSION;

ACETYLCHOLINE; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FOREARM; HUMANS; MALE; NITROPRUSSIDE; REGIONAL BLOOD FLOW; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASODILATION; VASODILATOR AGENTS;

EID: 84876674207     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.00841     Document Type: Article

References (19)

1. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011;17:1359-1370.
2. Facemire CS, Nixon AB, Griffths R, Hurwitz H, Coffman TM. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension. 2009;54:652-658.
3. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med. 1971;285:1182-1186.
4. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA. 2011;305: 487-494.
5. Drug Information Bevacizumab by European Medicine Agency (EMEA). Summary of product characteristics; 15/11/2012 Avastin-EMEA/H/C/000582-II/0053. 2009.
6. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol. 1998;274:H1054-H1058.
7. Janvier A, Nadeau S, Baribeau J, Perreault T. Role of vascular endothelial growth factor receptor 1 and vascular endothelial growth factor receptor 2 in the vasodilator response to vascular endothelial growth factor in the neonatal piglet lung. Crit Care Med. 2005;33:860-866.
8. Kappers MH, van Esch JH, Sleijfer S, Danser AH, van den Meiracker AH. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects. J Hypertens. 2009;27:2297-2309.
9. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER; VIVA Investigators. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation. 2003;107:1359-1365.
10. Wu JY, Wu XN, Ding L, Zhao YB, Ai B, Li Y, Hu X, Cheng G. Phase I safety and pharmacokinetic study of bevacizumab in Chinese patients with advanced cancer. Chin Med J. 2010;123:901-906.
11. Mayer EL, Dallabrida SM, Rupnick MA, Redline WM, Hannagan K, Ismail NS, Burstein HJ, Beckman JA. Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and fow-stimulated nitric oxide elaboration in humans. Hypertension. 2011;58:85-92.
12. Steeghs N, Gelderblom H, Roodt JO, Christensen O, Rajagopalan P, Hovens M, Putter H, Rabelink TJ, de Koning E. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res. 2008;14:3470-3476.
13. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcir-culation. Ann Oncol. 2008;19:927-934.
14. Prasad A, Dunnill GS, Mortimer PS, MacGregor GA. Capillary rarefaction in the forearm skin in essential hypertension. J Hypertens. 1995;13: 265-268.
15. Gasser P, Bühler FR. Nailfold microcirculation in normotensive and essential hypertensive subjects, as assessed by video-microscopy. J Hypertens. 1992;10:83-86.
16. Kappers MH, de Beer VJ, Zhou Z, Danser AH, Sleijfer S, Duncker DJ, van den Meiracker AH, Merkus D. Sunitinib-induced systemic vasocon-striction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension. 2012;59:151-157.
17. Horowitz JR, Rivard A, van der Zee R, Hariawala M, Sheriff DD, Esakof DD, Chaudhry GM, Symes JF, Isner JM. Vascular endo-thelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol. 1997;17:2793-2800.
18. Filep JG. Endogenous endothelin modulates blood pressure, plasma volume, and albumin escape after systemic nitric oxide blockade. Hypertension. 1997;30:22-28.
19. Mitsutomi N, Akashi C, Odagiri J, Matsumura Y. Effects of endogenous and exogenous nitric oxide on endothelin-1 production in cultured vascular endothelial cells. Eur J Pharmacol. 1999;364:65-73.